SS Innovations International, Inc. (Nasdaq: SSII) completed a private placement of its common stock on March 6, 2026, generating approximately $18.6 million in gross proceeds before offering expenses. The financing involved the sale of 5,774,839 shares of common stock, with company leadership and new investors participating in the offering.
The private placement consisted of two components. Company leadership, including Chairman and CEO Dr. Sudhir Srivastava, Vice-Chairman Dr. Frederic H. Moll, and director Tim Adams, purchased 1,300,006 shares at an average price of $4.00 per share, totaling approximately $5.2 million. Existing and new investors, led by existing shareholder Manipal Global Health Services, purchased 4,474,833 shares at $3.00 per share, totaling approximately $13.4 million.
This financing represents a significant development in the medical technology sector because it provides capital for a company focused on making robotic surgery more accessible globally. Surgical robotics has traditionally been dominated by expensive systems that limit adoption in many healthcare markets. SS Innovations' approach to developing affordable, user-friendly systems could potentially expand access to minimally invasive surgical techniques in regions where cost has been a barrier to adoption.
The company intends to use the net proceeds for working capital and general corporate purposes, specifically advancing global expansion efforts. According to Dr. Srivastava, the funding will support growth initiatives in India and other existing markets while preparing for entry into the United States and European Union markets. The company anticipates that the U.S. Food and Drug Administration will complete its review of the 510(k) premarket notification for the SSi Mantra surgical robotic system by mid-2026 and expects to obtain European Union CE marking certification in the same year.
The insider participation in this financing demonstrates confidence in the company's strategic direction and technology. Dr. Srivastava noted that this reflects commitment to democratizing access to world-class surgical robotic care. The continuing support from Manipal Global Health Services, a large existing shareholder, along with new investor participation, provides validation of the company's business model and growth potential.
For the healthcare industry, this development could signal increased competition in the surgical robotics market, potentially driving innovation and price competition. The SSi Mantra system features modular robotic arms, an ergonomic surgeon command center, 3D 4K visualization, and compatibility with over 40 different types of robotic endo-surgical instruments. The system has been clinically validated in India in more than 100 different surgical procedures, including cardiac surgery.
The broader implications of this funding extend to healthcare systems worldwide. If successful, SS Innovations' expansion could make advanced surgical robotics available to more hospitals and patients, potentially improving surgical outcomes while reducing healthcare costs. The company's focus on affordability aligns with global healthcare trends toward cost-effective medical technologies.
Investors can find additional information about the company at https://ssinnovations.com. The securities sold in this private placement have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or applicable exemption. This announcement does not constitute an offer to sell or solicitation to buy these securities.
